UNSPSC 51143205: Altinicline

This classification denotes a cholinergic agonist with the molecular formula C12H14N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RJ9V9V09VM, chemically known as pyridine, 3-ethynyl-5-((2s)-1-methyl-2-pyrrolidinyl)- but generally known as altinicline, which bears US NIH Compound Identifier 3036156. Altinicline most often comes in base and maleate forms. The term ALTINICLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44).

Most nations schedule altinicline under HS 29339990 and SITC 51577. As of Q4 2014, ALTINICLINE remains the US FDA Preferred Term for this commodity. Altinicline bears US NLM identifiers UMLS ID C2698073 and NCI Concept Code C77841. SMILES: CN1CCCC1C2=CN=CC(=C2)C#C.

UNSPSC 51143205 Altinicline is a Commodity code tracking procurement of pharmaceutical products, specifically naloxone and related drug-deactivation compounds used in community health and emergency response programs. State and local health departments and county public-health agencies are the primary issuing bodies acquiring these products, typically through competitive bidding processes with fixed-fee pricing models and annual volume commitments. The work involves procuring finished pharmaceutical units for emergency medical deployment and community harm-reduction initiatives, with vendors responsible for meeting pharmaceutical licensing, drug-free workplace certification, and E-Verify compliance requirements.

Seminole County, Florida represents the most concrete recent activity, issuing IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug-deactivation systems annually with quarterly delivery to the Seminole County Community Health Building, with bids due July 26, 2023. The Texas Health and Human Services Commission issued a parallel Request for Information (HHS0017013) in April 2026 exploring direct-to-manufacturer prescription programs, signaling state-level interest in streamlining pharmaceutical procurement channels beyond traditional pharmacy benefit managers and wholesalers. Florida and Texas show recent activity under this code, though the broader state and local market for altinicline-specific commodities appears narrow, with opportunities concentrated in health departments and county public-health systems pursuing emergency-response and community-health initiatives rather than widespread clinical deployment.